JP2007517038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007517038A5 JP2007517038A5 JP2006547319A JP2006547319A JP2007517038A5 JP 2007517038 A5 JP2007517038 A5 JP 2007517038A5 JP 2006547319 A JP2006547319 A JP 2006547319A JP 2006547319 A JP2006547319 A JP 2006547319A JP 2007517038 A5 JP2007517038 A5 JP 2007517038A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- solid dosage
- acidic functional
- acid
- functional group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007909 solid dosage form Substances 0.000 claims 17
- 230000002378 acidificating effect Effects 0.000 claims 11
- 125000000524 functional group Chemical group 0.000 claims 11
- 239000002253 acid Substances 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- 238000009498 subcoating Methods 0.000 claims 6
- 239000002702 enteric coating Substances 0.000 claims 4
- 238000009505 enteric coating Methods 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 2
- 235000008206 alpha-amino acids Nutrition 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 229940126409 proton pump inhibitor Drugs 0.000 claims 1
- 239000000612 proton pump inhibitor Substances 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 229940075420 xanthine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1065CH2003 | 2003-12-30 | ||
| PCT/US2004/043155 WO2005065726A1 (en) | 2003-12-30 | 2004-12-23 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517038A JP2007517038A (ja) | 2007-06-28 |
| JP2007517038A5 true JP2007517038A5 (https=) | 2008-01-31 |
Family
ID=34746655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006547319A Pending JP2007517038A (ja) | 2003-12-30 | 2004-12-23 | 薬学的組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070141150A1 (https=) |
| EP (1) | EP1699458A4 (https=) |
| JP (1) | JP2007517038A (https=) |
| CA (1) | CA2552440A1 (https=) |
| WO (1) | WO2005065726A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003000235A1 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
| BRPI0509971A (pt) * | 2004-04-15 | 2007-10-02 | Reddys Lab Inc Dr | uma forma de dosagem farmacêutica, comprimido e método de preparação |
| DE102005007059A1 (de) * | 2005-02-15 | 2006-08-24 | Röhm GmbH & Co. KG | Teilneutralisiertes anionisches (Meth)acrylat-Copolymer |
| RU2428176C2 (ru) | 2006-01-27 | 2011-09-10 | Юранд, Инк. | Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты |
| EP1820800A1 (en) | 2006-02-17 | 2007-08-22 | KRKA, tovarna zdravil, d.d., Novo mesto | Crystalline forms of duloxetine hydrochloride and processes for their preparation |
| KR20090005237A (ko) * | 2006-05-22 | 2009-01-12 | 테바 파마슈티컬 인더스트리즈 리미티드 | 둘록세틴 염산염 지연 방출형 제제 |
| JP5228359B2 (ja) * | 2007-04-12 | 2013-07-03 | ニプロ株式会社 | 主薬粒子及びその製造方法ならびに口腔内崩壊錠 |
| WO2008129501A2 (en) * | 2007-04-20 | 2008-10-30 | Wockhardt Research Centre | Pharmaceutical compositions of duloxetine |
| WO2009004649A2 (en) * | 2007-05-21 | 2009-01-08 | Sun Pharmaceutical Industries Limited | Enteric coated pharmaceutical compositions |
| EP2182929A2 (en) * | 2007-07-13 | 2010-05-12 | Synthon B.V. | Duloxetine formulations |
| WO2009087657A2 (en) * | 2007-11-03 | 2009-07-16 | Alkem Laboratories Ltd. | Stable pharmaceutical composition of duloxetine and process for its preparation |
| WO2009150238A2 (en) * | 2008-06-13 | 2009-12-17 | Krka, D.D. Novo Mesto | Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives |
| EP2133072A1 (en) * | 2008-06-13 | 2009-12-16 | KRKA, D.D., Novo Mesto | Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives |
| US20100040680A1 (en) * | 2008-08-15 | 2010-02-18 | Felix Lai | Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation |
| BRPI0919249B1 (pt) * | 2008-09-25 | 2017-12-19 | Isp Investments Inc. | Coating composition, method for coating solids and coated product |
| CN105101958B (zh) * | 2013-01-15 | 2019-05-17 | 纽斯尔特科学公司 | 治疗肺病状 |
| CN112823018A (zh) | 2018-06-20 | 2021-05-18 | 胺细拉健康公司 | 制备氨基酸组合物的方法 |
| JOP20200324A1 (ar) | 2018-06-20 | 2020-12-14 | Axcella Health Inc | تركيبات للعلاج والصحة تحتوي على أحماض أمينية ذات طعم مُر |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB8626936D0 (en) * | 1986-11-11 | 1986-12-10 | Ferrosan As | Treatment |
| JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
| US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
| SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5910319A (en) * | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
| DK173431B1 (da) * | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
| JP3550559B2 (ja) * | 2001-10-18 | 2004-08-04 | アサヒ飲料株式会社 | グリシン含有飲料 |
-
2004
- 2004-12-23 EP EP04815257A patent/EP1699458A4/en not_active Withdrawn
- 2004-12-23 CA CA002552440A patent/CA2552440A1/en not_active Abandoned
- 2004-12-23 JP JP2006547319A patent/JP2007517038A/ja active Pending
- 2004-12-23 WO PCT/US2004/043155 patent/WO2005065726A1/en not_active Ceased
- 2004-12-23 US US10/596,915 patent/US20070141150A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007517038A5 (https=) | ||
| JP2004521123A5 (https=) | ||
| JP2013537907A5 (https=) | ||
| JP2010536714A5 (https=) | ||
| BR0210971A (pt) | Formas inovadoras de dosagem de benzimidazol substituìdo e método para usar as mesmas | |
| JP2015537002A5 (https=) | ||
| JP2006287244A5 (https=) | ||
| JP2020073472A5 (https=) | ||
| JP2005518361A5 (https=) | ||
| RU2010116863A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| IL308807B2 (en) | Combination therapy for treating cancer | |
| RS59978B1 (sr) | Stabilne formulacije linaklotida | |
| FI3746467T3 (fi) | Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö | |
| EA200901365A1 (ru) | Стабилизированная фармацевтическая композиция, содержащая прегабалин | |
| RU2010111139A (ru) | Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства | |
| WO2010151495A3 (en) | Materials and methods for treating and preventing viral infections | |
| EP1374863A4 (en) | AMINO ACID COMPOSITIONS TO REDUCE LIGHT-INFFICIENCY | |
| JP2016519106A5 (https=) | ||
| EP4294454B1 (en) | Anti-viral peptides and compositions and methods of use thereof | |
| ATE361743T1 (de) | Beschichtete minitabletten von venlafaxinhydrochlorid mit verlängerter freisetzung | |
| ATE497968T1 (de) | Verbindungen zur diagnose von mit der vcam- expression assoziierten krankheiten | |
| JP2006508972A5 (https=) | ||
| JP2020117504A5 (https=) | ||
| JP2013510158A5 (https=) | ||
| NO996049D0 (no) | Kontrollert-frigjøring farmasoeytisk preparat med ACE inhibitor som aktivt middel |